Two coronavirus vaccines 'produce immune response': trials
Two coronavirus vaccine candidates have proven safe for humans and produced strong immune reactions among patients involved in separate clinical trials, doctors said Monday.
The first trial among more than 1,000 adults in Britain found that the vaccine induced "strong antibody and T cell immune responses" against the novel coronavirus.
A separate trial in China involving more than 500 people showed most had developed widespread antibody immune response.
The studies, published in The Lancet medical journal, constitute a major step on the road towards a COVID-19 vaccine that is effective and safe for widespread use.
The authors of the studies said that they encountered few adverse side effects from the vaccine candidates.
However, they cautioned that more research was needed, particularly among older adults, who are disproportionately at risk of dying of COVID-19.
ALSO READ:
ANC MP dies of Covid-19 illness
Mmola, who served as a delegate of the National Council of Provinces (NCOP), passed away on Saturday. She represented the province of Mpumalanga. Presiding officers, Thandi Modise and Amos Masondo, have expressed their condolences on the passing of Mmola.
Co-author Sarah Gilbert from the University of Oxford said the results "hold promise".
"If our vaccine is effective, it is a promising option as these types of vaccine can be manufactured at large scale."